Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring

BACKGROUND: Natalizumab, a highly specific α4-integrin antagonist, , has recently been registered across the Middle East and North Africa region. It improves clinical and magnetic resonance imaging (MRI) outcomes and reduces the rate of relapse and disability progression in relapsing-remitting multi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Alroughani, Raed A, Aref, Hany M, Bohlega, Saeed A, Dahdaleh, Maurice P, Feki, Imed, Al Jumah, Mohammed A, Al-Kawi, Muhammad Z, Koussa, Salam F, Sahraian, Mohamad A, Alsharoqi, Isa A, Yamout, Bassem I
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2014
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3927624/
https://ncbi.nlm.nih.gov/pubmed/24521176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2377-14-27
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi